Washington-Watch
FDA General
More in FDA General
Complete responses in 21% of patients treated with single-agent revumenib
Can severe neutropenia associated with the schizophrenia drug be monitored without it?
Health news and commentary gathered by 鶹ý staff
Novel treatment is indicated for children and adults with the rare disorder
Agency spent over 15 years crafting the guidelines
Agency's decision on obeticholic acid in PBC follows negative advisory committee meeting
Advocates look to undo Biden administration's policies
Obecabtagene autoleucel has no requirement for a REMS program
ProSense device would be indicated with adjuvant endocrine therapy for some low-risk patients
Data review shows that oral phenylephrine is not effective as a decongestant, agency says
Valeda photobiomodulation system slowed disease progression and improved vision
A look at Trump's history and ideas floated on the campaign trail
